Female sex, chronic kidney disease, enrollment date, new-onset atrial fibrillation predict CVEs
TUESDAY, Aug. 9, 2016 (HealthDay News) — For patients undergoing transcatheter aortic valve replacement (TAVR), predictors of cerebrovascular events (CVEs) include female sex, chronic kidney disease, new-onset atrial fibrillation, and enrollment date, according to a review published in the Aug. 16 issue of the Journal of the American College of Cardiology.
Vincent Auffret, M.D., from the Quebec Heart & Lung Institute in Canada, and colleagues conducted a systematic review to examine predictors of 30-day CVE post-TAVR. Data were included from 64 studies, involving 72,318 patients (2,385 with a CVE within 30-day post-TAVR).
The researchers found that the incidence of CVE varied from 1 to 11 percent, with no significant differences between single and multicenter studies. Based on the summary risk ratios the risk was lower for men (risk ratio, 0.82; P = 0.02) and higher for patients with chronic kidney disease, for patients with new-onset atrial fibrillation post-TAVR, and for procedures performed within the first half of center experience (risk ratios, 1.29 [P = 0.03], 1.85 [P = 0.005], and 1.55 [P = 0.003], respectively). There was a trend toward higher risk of CVE with use of balloon post-dilation (risk ratio, 1.43; P = 0.07). CVE was not predicted by valve type or approach.
“This study provides effect estimates to identify high-risk TAVR patients for early CVE, providing possible guidance for tailored preventive strategies,” the authors write.
Several authors disclosed financial ties to the medical device industry.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
